Legend Biotech Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) has announced its participation in several upcoming investor conferences. The events include the BMO Biopharma Spotlight Series: Oncology Day on November 9, 2022, and the Cowen 6th Annual IO Next Summit on November 11, 2022, both featuring presentations by CEO Ying Huang, Ph.D. Further conferences will take place in Miami on November 14, London on November 17, and New York on November 29, culminating with the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022.

SOMERSET, N.J.--(BUSINESS WIRE)-- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences:

Event: BMO Biopharma Spotlight Series: Oncology Day (Virtual)
Fireside Chat Date & Time: Wednesday, November 9, 2022 at 1:30pm ET
Presenter: Ying Huang, Ph.D., CEO

Event: Cowen 6th Annual IO Next Summit (Virtual)
Fireside Chat Date & Time: Friday, November 11, 2022 at 1:10pm ET
Presenter: Ying Huang, Ph.D., CEO

Event: JP Morgan Equity Opportunities Forum
Location: Miami, Florida
Date: Monday, November 14, 2022

Event: Jefferies London Healthcare Conference
Location: London
Fireside Chat Date & Time: Thursday, November 17, 2022 at 2:40pm GMT
Presenter: Ying Huang, Ph.D., CEO

Event: Piper 34^th Annual Healthcare Conference
Location: New York, New York
Fireside Chat Date & Time: Tuesday, November 29, 2022 at 3:00pm ET
Presenter: Ying Huang, Ph.D., CEO

Event: Evercore ISI 5^th Annual HealthCONx Conference (Virtual)
Fireside Chat Date & Time: Wednesday, November 30, 2022 at 9:40am ET
Presenter: Ying Huang, Ph.D., CEO

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221104005618/en/

Investor Contacts:

Joanne Choi, Senior Manager, Investor Relations, Legend Biotech

joanne.choi@legendbiotech.com



Crystal Chen, Manager, Investor Relations, Legend Biotech

crystal.chen@legendbiotech.com



Press Contact:

Tina Carter, Corporate Communications Lead, Legend Biotech

tina.carter@legendbiotech.com

(908) 331-5025

Source: Legend Biotech

FAQ

What is the schedule for Legend Biotech's upcoming investor conferences in November 2022?

Legend Biotech will participate in several conferences: BMO Biopharma Spotlight Series on November 9, Cowen 6th Annual IO Next Summit on November 11, JP Morgan Equity Opportunities Forum on November 14, Jefferies London Healthcare Conference on November 17, Piper 34th Annual Healthcare Conference on November 29, and Evercore ISI 5th Annual HealthCONx Conference on November 30.

Who will present at Legend Biotech's investor conferences?

CEO Ying Huang, Ph.D., will present at the BMO Biopharma Spotlight Series, Cowen 6th Annual IO Next Summit, and Jefferies London Healthcare Conference.

Where will Legend Biotech's investor events be held?

Events will be held virtually and in-person locations such as Miami, London, and New York.

What is the significance of the BMO Biopharma Spotlight Series for Legend Biotech?

The BMO Biopharma Spotlight Series offers Legend Biotech a platform to discuss its latest advancements and therapies in oncology.

How can investors contact Legend Biotech after the investor conferences?

Investors can contact Joanne Choi or Crystal Chen in Investor Relations through their respective emails for inquiries.